{"id":"NCT00308308","sponsor":"Mannkind Corporation","briefTitle":"Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes","officialTitle":"A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 1 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Basal and Prandial Insulin Over a 52-Week Treatment Period and a 4-Week Follow Up","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-02","primaryCompletion":"2008-07","completion":"2008-08","firstPosted":"2006-03-29","resultsPosted":"2014-10-16","lastUpdate":"2014-10-16"},"enrollment":589,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes, Type I"],"interventions":[{"type":"DRUG","name":"Technosphere Insulin","otherNames":[]},{"type":"DRUG","name":"Active comparator","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"To determine the safety and efficacy of inhaled insulin in the treatment of type 1 diabetes","primaryOutcome":{"measure":"Compare the Mean Change From Baseline to Week 52 in HbA1c","timeFrame":"Baseline to Week 52","effectByArm":[{"arm":"TI + Insulin Glargine","deltaMin":-0.13,"sd":0.058},{"arm":"Insulin Aspart + Insulin Glargine","deltaMin":-0.37,"sd":0.059}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":8,"exclusionCount":3},"locations":{"siteCount":129,"countries":["United States","Argentina","Brazil","Canada","Chile","Mexico","Poland","Russia","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":52,"n":293},"commonTop":["Hypoglycaemia","Cough","Upper respiratory tract infection","Nasopharyngitis","Influenza"]}}